EFFECTS OF MELATONIN ON BLOOD PRESSURE IN STRESS-INDUCED HYPERTENSION IN RATS
- 1 October 2008
- journal article
- research article
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 35 (10), 1258-1264
- https://doi.org/10.1111/j.1440-1681.2008.05000.x
Abstract
Melatonin, acting through its receptors, is involved in numerous physiological processes, including blood pressure (BP) regulation. In present study, the effect of melatonin inhibition on stress-induced hypertension was investigated. The hypertensive model consisted of male Sprague-Dawley rats subjected to electrical foot-shock combined with noise. Microinjection of melatonin (0.1 and 1.0 mmol/L) into the anterior hypothalamic area (AHA) produced a fall in BP in nomortensive rats and stress-induced hypertensive rats (SIHR). Luzindole (10 mmol/L), a competitive antagonist of melatonin MT1 and MT2 receptors, almost completely abolished the depressor effect of melatonin, the MT2 receptor-specific antagonist 4-phenyl-2-propionamidotetralin (10 mmol/L) partially blocked (by approximately 60%) the depressor effect of melatonin, whereas the MT3 receptor-selective antagonist prazosin (10 mmol/L) failed to antagonize the effects of melatonin. Brain microdialysis was performed in the AHA and the rostral ventrolateral medulla (RVLM). Melatonin and amino acids in the dialysate samples collected were detected by high-performance liquid chromatography combined with fluorescence detection. The results indicated that melatonin concentrations in the AHA were reduced in SIHR. Microinjection of melatonin into the AHA decreased glutamate release and increased GABA and taurine release in the RVLM, which were paralleled by a decrease in arterial pressure. The mRNA expression of MT2 in the AHA of SIHR was higher than that in normotensive control rats, whereas there was no significant difference in MT1 mRNA expressin between the two groups. The results of the present study suggest that both a decrease of melatonin and an increase in the MT2 receptor in the AHA are involved in the manifestation of stress-induced hypertension. Both MT1 and MT2 receptors participated in the antihypertensive effect of melatonin in the AHA. The antihypertensive effect of melatonin was related to the decreases in the excitatory amino acid glutamate and increases in the inhibitory amino acids taurine and GABA in the RVLM.Keywords
This publication has 28 references indexed in Scilit:
- Melatonin Reduces Night Blood Pressure in Patients with Nocturnal HypertensionAmerican Journal Of Medicine, 2006
- The Circadian Clock, Light/Dark Cycle and Melatonin Are Differentially Involved in the Expression of Daily and Photoperiodic Variations in mt1 Melatonin Receptors in the Siberian and Syrian HamstersNeuroendocrinology, 2001
- Photic Regulation of mt1 Melatonin Receptors in the Siberian Hamster Pars Tuberalis and Suprachiasmatic Nuclei: Involvement of the Circadian Clock and Intergeniculate LeafletJournal of Neuroendocrinology, 2000
- Molecular and pharmacological evidence for MT1 melatonin receptor subtype in the tail artery of juvenile Wistar ratsBritish Journal of Pharmacology, 1999
- Effects of melatonin on vascular reactivity, catecholamine levels, and blood pressure in healthy menThe American Journal of Cardiology, 1999
- Melatonin mediates two distinct responses in vascular smooth muscleEuropean Journal of Pharmacology, 1998
- Influences of melatonin administration on the circulation of women.American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 1998
- Antihypertensive Action of Melatonin in the Spontaneously Hypertensive RatClinical and Experimental Hypertension. Part A: Theory and Practice, 1987
- Melatonin in Serum and the Pineal of Spontaneously Hypertensive RatsClinical and Experimental Hypertension. Part A: Theory and Practice, 1984
- Effect of pinealectomy on arterial blood pressure and food and water intake in the ratJournal of Endocrinological Investigation, 1978